Moderna (MRNA)
(Delayed Data from NSDQ)
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $86.91 +0.07 (0.08%) 7:10 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.84 USD
+0.22 (0.25%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $86.91 +0.07 (0.08%) 7:10 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Zacks News
Pre-Markets Down on Omicron Fears
by Zacks Equity Research
Pre-Markets Down on Omicron Fears
Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns
by Zacks Equity Research
Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.
Reversal on Omicron Prospects Send Markets Down
by Mark Vickery
Moderna's (MRNA) Stephane Bancel told the Financial Times that the scientists he's been talking to say fighting Omicron is "not going to be good."
J&J (JNJ) to Explore Omicron Version of its COVID Vaccine
by Zacks Equity Research
J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant
Stock Market News for Nov 30, 2021
by Zacks Equity Research
Benchmarks closed higher on Monday after President Joe Biden reassured Americans that despite the latest Omicron coronavirus variant scare, the country will not undergo shutdowns or lockdowns.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax
Nice Relief Rally on Biotech Assurances, Home Sales Data
by Mark Vickery
The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.
Nice Relief Rally on Biotech Assurances, Home Sales Data
by Mark Vickery
The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.
Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?
by Zacks Equity Research
Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.
ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus
by Sanghamitra Saha
The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.
Wall Street Tumbles on Resurgence of Coronavirus
by Zacks Equity Research
Wall Street Tumbles on Resurgence of Coronavirus.
Black Friday Meets "Black Friday:" New Covid Variant Hits Markets
by Mark Vickery
A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.
Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe
J&J (JNJ) Gets First Full Approval for COVID Jab in Canada
by Zacks Equity Research
Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
by Zacks Equity Research
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.
Will Thanksgiving Help Oil & Energy ETFs Despite Covid Fears?
by Sanghamitra Saha
Higher Thanksgiving demand should help oil and energy ETFs despite the renewed COVID fears.
The Zacks Analyst Blog Highlights: Alibaba, Lowe's, American Express, Boeing and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Lowe's, American Express, Boeing and Moderna
Moderna ETFs to Rally on Positive COVID-19 Booster Shot News
by Sweta Jaiswal, FRM
Moderna is expected to gain approval for booster shots for its COVID-19 vaccine.
Top Stock Reports for Alibaba, Lowe's & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Lowe's Companies, Inc. (LOW), and American Express Company (AXP).
FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults
by Zacks Equity Research
The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.
Stock Market News for Nov 22, 2021
by Zacks Equity Research
Wall Street closed mixed on Friday to end a choppy week.
FDA Gives Authorization to Two COVID-19 Boosters
by Zacks Equity Research
FDA Gives Authorization to Two COVID-19 Boosters
FDA Authorizes Covid Boosters; New Fed Chair Soon?
by Mark Vickery
Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."
AstraZeneca (AZN), Moderna's Heart Failure Study Successful
by Zacks Equity Research
AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.
Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab
by Zacks Equity Research
Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.